Product

Company

NCT00841945·1 site·ClinicalTrials.gov

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

French Innovative Leukemia Organisation

CHOP 14 R regimen of chemotherapy is a good standard in the treatment of agressive and localized B lymphoma. Interest of the radiotheraphy

Age

18–75

Sex

ALL

Healthy volunteers

Not accepted

Age\< 18 and \> 75 years
other type of lymphoma
CD20 negative
Ann Arbor stage \>II or bulk \> 7 cm
HIV positive
Contraindication to Rituximab use according to Sm PC
Containdication to antracyclin
cancer or history of cancer , excepted in situ cancer of the cervix or skin epithelioma
Refusal of sign the informed consent

The record

StatusTerminated

PhasePhase 3

Taking part334

StartedApr 2005

UpdatedFeb 23, 2017

Conditions

Where1

Clareo Health | Treatment of Aggressive Localized Lymphoma